Inborn errors of immunity are associated with increased COVID-19-related hospitalization and intensive care compared to the general population.

Lindahl H, Kahn F, Nilsdotter-Augustinsson Å, Fredrikson M, Hedberg P, Killander Möller I, Hansson L, Blixt L, Eketorp Sylvan S, Österborg A, Aleman S, Carlander C, Nyström S, Bergman P

J Allergy Clin Immunol - (-) - [2024-10-22; online 2024-10-22]

It is thought that patients with inborn errors of immunity (IEI) are more susceptible to severe coronavirus disease 2019 (COVID-19) than the general population, but a quantification of this potential risk is largely missing. We assessed the impact of COVID-19 on patients with IEI. A nationwide cohort study was performed to estimate the relative risk (RR) for hospitalization, intensive care, and death within 30 days after a positive severe acute respiratory syndrome coronavirus 2 test result in an IEI population (n = 2392) compared to the general population (n = 8,270,705) using data from Swedish national registries. Three time periods were studied: the prevaccination period, and the Alpha/Delta and Omicron periods. Adjustment was made for demographics, income, comorbidities, and vaccination status. During the prevaccination period, 25.2% of the IEI population was hospitalized, compared to 17.5% and 5.2% during the Alpha/Delta and Omicron periods, respectively. For the 3 time periods, the adjusted RR [95% confidence interval] for hospitalization in the IEI population compared to the general population was 3.1 [2.1-4.2], 3.5 [2.4-4.8], and 4.3 [2.5-6.7], respectively. The respective values for intensive care after COVID-19 were 5.6 [2.6-10.8], 4.7 [1.7-10.1], and 4.7 [1.7-10.1] for the 3 periods. Five patients (0.6%) in the IEI population died within 30 days of a positive PCR test result compared to 18,773 (0.2%) in the general population during the 3 study periods. Patients with IEI had a 3 to 4 times higher risk for hospitalization and a 5 times higher risk for intensive care during COVID-19 compared to the general population.

PubMed 39447887

DOI 10.1016/j.jaci.2024.10.013

Crossref 10.1016/j.jaci.2024.10.013

pii: S0091-6749(24)01125-4